Last $6.50 USD
Change Today -0.06 / -0.91%
Volume 36.5K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 3:57 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Key Developments

Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer

Regulus Therapeutics Inc. announced the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus' microRNA clinical portfolio and will serve as a key member of its executive leadership team. Grint joined Regulus from Cerexa Inc. where he served as President and was responsible for the oversight of anti-infective product development.

Regulus Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Regulus Therapeutics Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues under strategic alliances and collaborations of $1,631,000 against $3,238,000 a year ago. Loss from operations was $10,705,000 against $5,550,000 a year ago. Loss before income taxes was $12,740,000 against $7,239,000 a year ago. Net loss was $12,741,000 or $0.30 per basic and diluted share against $7,229,000 or $0.20 per basic and diluted share a year ago.

Regulus Therapeutics Inc. to Report Q1, 2014 Results on May 08, 2014

Regulus Therapeutics Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 08, 2014

Regulus Therapeutics Inc., Q1 2014 Earnings Call, May 08, 2014

Regulus Therapeutics Inc., Q1 2014 Earnings Call, May 08, 2014

Regulus Therapeutics Inc., Annual General Meeting, May 22, 2014

Regulus Therapeutics Inc., Annual General Meeting, May 22, 2014., at 09:00 Pacific Standard Time. Location: 3545 John Hopkins Ct., Suite 210. Agenda: To consider Election of Directors; to consider the ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm of the company for the year ending December 31, 2014; and to transact such other business as may properly come before the meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $6.50 USD -0.06

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.16 AUD -0.005
Enzon Pharmaceuticals Inc $1.09 USD +0.035
Galena Biopharma Inc $2.85 USD +0.035
Silence Therapeutics PLC 226.00 GBp -9.00
Tekmira Pharmaceuticals Corp C$11.10 CAD -0.23
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.